Prognostic significance of p53 immunostaining in epithelial ovarian cancer

Lynn C. Hartmann, Karl C. Podratz, Gary Keeney, Nermeen A. Kamel, John H. Edmonson, Joseph P. Grill, John Q. Su, Jerry A. Katzmann, Patrick C. Roche

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

Purpose: To evaluate the prognostic significance of p53 expression in epithelial ovarian cancer, including a subset of stage I patients, and to look for correlations between p53 expression and other disease parameters, including stage, grade, age, histologic subtype, second-look results, ploidy, and percent S phase. Patients and Methods: We analyzed p53 expression in 284 patients with epithelial ovarian cancer using immunohistochemical techniques in paraffin-embedded specimens. There were 36 patients with stage I disease, 20 with stage II disease, 186 with stage III disease, and 42 with stage IV disease. Results: p53 immunoreactivity was present in 177 cases (62%). p53 expression was associated with grade 3 to 4 disease (P = .003). The following factors were associated with a decrease in overall survival in a univariate analysis: stage III or IV disease (P = .0001), grade 3 or 4 disease (P = .0001), age above the median (P = .0002), and p53 reactivity (P = .04). In a multivariate analysis, stage, grade, and age retained independent prognostic significance. In the subset of 36 stage I patients, p53 positivity approached statistical significance (P = .10) as a negative prognostic factor in a univariate analysis. Conclusion: Abnormalities of p53 expression occur commonly in epithelial ovarian cancer. Although associated with decreased survival in a univariate analysis, this biologic marker did not retain independent prognostic significance in a multivariate analysis. p53 expression should be studied in a larger cohort of early-stage patients, where accurate prognostic information is needed to direct therapy.

Original languageEnglish (US)
Pages (from-to)64-69
Number of pages6
JournalJournal of Clinical Oncology
Volume12
Issue number1
StatePublished - Jan 1994

Fingerprint

Multivariate Analysis
Survival
Ovarian epithelial cancer
Ploidies
S Phase
Paraffin
Biomarkers
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hartmann, L. C., Podratz, K. C., Keeney, G., Kamel, N. A., Edmonson, J. H., Grill, J. P., ... Roche, P. C. (1994). Prognostic significance of p53 immunostaining in epithelial ovarian cancer. Journal of Clinical Oncology, 12(1), 64-69.

Prognostic significance of p53 immunostaining in epithelial ovarian cancer. / Hartmann, Lynn C.; Podratz, Karl C.; Keeney, Gary; Kamel, Nermeen A.; Edmonson, John H.; Grill, Joseph P.; Su, John Q.; Katzmann, Jerry A.; Roche, Patrick C.

In: Journal of Clinical Oncology, Vol. 12, No. 1, 01.1994, p. 64-69.

Research output: Contribution to journalArticle

Hartmann, LC, Podratz, KC, Keeney, G, Kamel, NA, Edmonson, JH, Grill, JP, Su, JQ, Katzmann, JA & Roche, PC 1994, 'Prognostic significance of p53 immunostaining in epithelial ovarian cancer', Journal of Clinical Oncology, vol. 12, no. 1, pp. 64-69.
Hartmann LC, Podratz KC, Keeney G, Kamel NA, Edmonson JH, Grill JP et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. Journal of Clinical Oncology. 1994 Jan;12(1):64-69.
Hartmann, Lynn C. ; Podratz, Karl C. ; Keeney, Gary ; Kamel, Nermeen A. ; Edmonson, John H. ; Grill, Joseph P. ; Su, John Q. ; Katzmann, Jerry A. ; Roche, Patrick C. / Prognostic significance of p53 immunostaining in epithelial ovarian cancer. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 1. pp. 64-69.
@article{6321d0e1845c482693cd8caac3b1644f,
title = "Prognostic significance of p53 immunostaining in epithelial ovarian cancer",
abstract = "Purpose: To evaluate the prognostic significance of p53 expression in epithelial ovarian cancer, including a subset of stage I patients, and to look for correlations between p53 expression and other disease parameters, including stage, grade, age, histologic subtype, second-look results, ploidy, and percent S phase. Patients and Methods: We analyzed p53 expression in 284 patients with epithelial ovarian cancer using immunohistochemical techniques in paraffin-embedded specimens. There were 36 patients with stage I disease, 20 with stage II disease, 186 with stage III disease, and 42 with stage IV disease. Results: p53 immunoreactivity was present in 177 cases (62{\%}). p53 expression was associated with grade 3 to 4 disease (P = .003). The following factors were associated with a decrease in overall survival in a univariate analysis: stage III or IV disease (P = .0001), grade 3 or 4 disease (P = .0001), age above the median (P = .0002), and p53 reactivity (P = .04). In a multivariate analysis, stage, grade, and age retained independent prognostic significance. In the subset of 36 stage I patients, p53 positivity approached statistical significance (P = .10) as a negative prognostic factor in a univariate analysis. Conclusion: Abnormalities of p53 expression occur commonly in epithelial ovarian cancer. Although associated with decreased survival in a univariate analysis, this biologic marker did not retain independent prognostic significance in a multivariate analysis. p53 expression should be studied in a larger cohort of early-stage patients, where accurate prognostic information is needed to direct therapy.",
author = "Hartmann, {Lynn C.} and Podratz, {Karl C.} and Gary Keeney and Kamel, {Nermeen A.} and Edmonson, {John H.} and Grill, {Joseph P.} and Su, {John Q.} and Katzmann, {Jerry A.} and Roche, {Patrick C.}",
year = "1994",
month = "1",
language = "English (US)",
volume = "12",
pages = "64--69",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Prognostic significance of p53 immunostaining in epithelial ovarian cancer

AU - Hartmann, Lynn C.

AU - Podratz, Karl C.

AU - Keeney, Gary

AU - Kamel, Nermeen A.

AU - Edmonson, John H.

AU - Grill, Joseph P.

AU - Su, John Q.

AU - Katzmann, Jerry A.

AU - Roche, Patrick C.

PY - 1994/1

Y1 - 1994/1

N2 - Purpose: To evaluate the prognostic significance of p53 expression in epithelial ovarian cancer, including a subset of stage I patients, and to look for correlations between p53 expression and other disease parameters, including stage, grade, age, histologic subtype, second-look results, ploidy, and percent S phase. Patients and Methods: We analyzed p53 expression in 284 patients with epithelial ovarian cancer using immunohistochemical techniques in paraffin-embedded specimens. There were 36 patients with stage I disease, 20 with stage II disease, 186 with stage III disease, and 42 with stage IV disease. Results: p53 immunoreactivity was present in 177 cases (62%). p53 expression was associated with grade 3 to 4 disease (P = .003). The following factors were associated with a decrease in overall survival in a univariate analysis: stage III or IV disease (P = .0001), grade 3 or 4 disease (P = .0001), age above the median (P = .0002), and p53 reactivity (P = .04). In a multivariate analysis, stage, grade, and age retained independent prognostic significance. In the subset of 36 stage I patients, p53 positivity approached statistical significance (P = .10) as a negative prognostic factor in a univariate analysis. Conclusion: Abnormalities of p53 expression occur commonly in epithelial ovarian cancer. Although associated with decreased survival in a univariate analysis, this biologic marker did not retain independent prognostic significance in a multivariate analysis. p53 expression should be studied in a larger cohort of early-stage patients, where accurate prognostic information is needed to direct therapy.

AB - Purpose: To evaluate the prognostic significance of p53 expression in epithelial ovarian cancer, including a subset of stage I patients, and to look for correlations between p53 expression and other disease parameters, including stage, grade, age, histologic subtype, second-look results, ploidy, and percent S phase. Patients and Methods: We analyzed p53 expression in 284 patients with epithelial ovarian cancer using immunohistochemical techniques in paraffin-embedded specimens. There were 36 patients with stage I disease, 20 with stage II disease, 186 with stage III disease, and 42 with stage IV disease. Results: p53 immunoreactivity was present in 177 cases (62%). p53 expression was associated with grade 3 to 4 disease (P = .003). The following factors were associated with a decrease in overall survival in a univariate analysis: stage III or IV disease (P = .0001), grade 3 or 4 disease (P = .0001), age above the median (P = .0002), and p53 reactivity (P = .04). In a multivariate analysis, stage, grade, and age retained independent prognostic significance. In the subset of 36 stage I patients, p53 positivity approached statistical significance (P = .10) as a negative prognostic factor in a univariate analysis. Conclusion: Abnormalities of p53 expression occur commonly in epithelial ovarian cancer. Although associated with decreased survival in a univariate analysis, this biologic marker did not retain independent prognostic significance in a multivariate analysis. p53 expression should be studied in a larger cohort of early-stage patients, where accurate prognostic information is needed to direct therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028009626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028009626&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 64

EP - 69

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -